Becton Dickinson and Company11.13.15
Becton Dickinson and Company is having quite a banner year.
In March, the company completed its $12.2 billion acquisition of CareFusion, creating one of the five largest medical device companies in the world, with a range of offerings for pharmacies and hospitals.
Now, the bulked-up firm has received Frost & Sullivan’s 2015 Global Company of the Year Award for its Clinical and Research Flow Cytometry.
Frost & Sullivan analysts independently evaluated candidates for the Global Company of the Year Award based on three key factors: visionary innovation, performance and customer impact. BD was recognized for its large and diverse customer base, broad product portfolio, consistent track record of reliability and supply chain excellence, and quality customer service among other factors, company officials said.
“BD offers robust products that incorporate innovative hardware, software, multiple reagents (including a broad portfolio of bright fluorescent dyes), an automated setup and stringent quality control,” said Divyaa Ravishankar, team leader, senior industry analyst and associate fellow at Frost & Sullivan. “In addition to being first to market, BD has established clear credibility for its products among end users.”
BD’s principal Biosciences product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media and supplements for biopharmaceutical manufacturing.
“We are honored to be recognized by Frost & Sullivan,” said Claude Dartiguelongue, worldwide president of Biosciences for BD. “For more than 40 years, BD has partnered with our global research and clinical customers to expand knowledge of the single cell. Today, these discoveries and applications help to improve the diagnosis and understanding of many different diseases impacting the world.”
BD develops technology and solutions that address medication management and patient safety; support infection prevention practices; equip surgical and interventional procedures; improve drug delivery; aid anesthesiology and respiratory care; advance cellular research and applications; enhance the diagnosis of infectious diseases and cancers; and support the management of diabetes. The Franklin Lakes, N.J.-based company employs more than 45,000 associates in 50 countries.
In March, the company completed its $12.2 billion acquisition of CareFusion, creating one of the five largest medical device companies in the world, with a range of offerings for pharmacies and hospitals.
Now, the bulked-up firm has received Frost & Sullivan’s 2015 Global Company of the Year Award for its Clinical and Research Flow Cytometry.
Frost & Sullivan analysts independently evaluated candidates for the Global Company of the Year Award based on three key factors: visionary innovation, performance and customer impact. BD was recognized for its large and diverse customer base, broad product portfolio, consistent track record of reliability and supply chain excellence, and quality customer service among other factors, company officials said.
“BD offers robust products that incorporate innovative hardware, software, multiple reagents (including a broad portfolio of bright fluorescent dyes), an automated setup and stringent quality control,” said Divyaa Ravishankar, team leader, senior industry analyst and associate fellow at Frost & Sullivan. “In addition to being first to market, BD has established clear credibility for its products among end users.”
BD’s principal Biosciences product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media and supplements for biopharmaceutical manufacturing.
“We are honored to be recognized by Frost & Sullivan,” said Claude Dartiguelongue, worldwide president of Biosciences for BD. “For more than 40 years, BD has partnered with our global research and clinical customers to expand knowledge of the single cell. Today, these discoveries and applications help to improve the diagnosis and understanding of many different diseases impacting the world.”
BD develops technology and solutions that address medication management and patient safety; support infection prevention practices; equip surgical and interventional procedures; improve drug delivery; aid anesthesiology and respiratory care; advance cellular research and applications; enhance the diagnosis of infectious diseases and cancers; and support the management of diabetes. The Franklin Lakes, N.J.-based company employs more than 45,000 associates in 50 countries.